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http://dx.doi.org/10.1016/j.bgm.201Abstract Warfarin is a commonly prescribed oral anticoagulant used for prophylaxis and treat-
ment of deep vein thrombosis, myocardial infarction, heart valve replacement, pulmonary em-
bolisms, and other thromboembolic disorders. Because overdosing ofwarfarin is fatal to patients
and only a few studies are available on the Indian population, the present study was undertaken
to develop genotyping assays for themonitoring of patients undergoing warfarin therapy specific
to the Indian population. Warfarin dosing is correlated with polymorphisms in VKORC1 (vitamin K
epoxide reductase complex 1) and CYP2C9 (cytochrome P450 family 2, subfamily C, polypeptide
9) genes.Hence, this studywasundertaken toassess the impact of these genetic variations (SNPs)
in VKORC1 and CYP2C9 genes of Indian patients on warfarin therapy. In the present study,
genomic DNA samples from 136 individuals (patients on stabilized warfarin therapy) were
analyzed through polymerase chain reaction (PCR) and DNA sequencing. Furthermore, the
observed SNPs were correlated with the dosage pattern in order to understand the genotypee
phenotype correlation significance. Additionally, an amplification refractory mutation system
PCR-based genotyping assay was developed for the VKORC1 e1639G>A allele, as a rapid and
cost-effective detection tool. The analysis of samples from warfarin-sensitive patients showedof Genetics and Biotechnology, Osmania University, Hyderabad 500007, India.
l.com (T. Shukla).
an Genomic Medicine and Biomarker Society. Published by Elsevier Taiwan LLC. All rights reserved.
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148 T. Shukla et al.that 84.78% of participants had mutant alleles in either the CYP2C9 or the VKORC1 gene. A novel
mutationwithan insertionofGat3725position (Ins-Ge1586with respect to the start codon) in the
promoter region of theVKORC1 genedalongwith theVKORC1e1639G>A alleledwas observed in
four patients, all of whomwere on a higher dosage of warfarin (>7mg/d). Our results clearly indi-
cate that there is a variation in the dosage pattern associated with the VKORC1e1639G>A geno-
type in the presence of this novel promoter insertion, further suggesting the need for large-scale
studies to be conducted on Indian populations for the validation of warfarin sensitivity tests.
Copyrightª 2013, TaiwanGenomic Medicine and Biomarker Society. Published by Elsevier Taiwan
LLC. All rights reserved.Introduction
Warfarin, a coumarin anticoagulant, is widely used in
treating atrial fibrillation, heart valve prosthesis, recurrent
stroke, deep vein thrombosis (DVT), myocardial infarction,
and pulmonary embolism.1 However, narrowed therapeutic
index and increased risk of clots during subtherapeutic or
bleeding upon supertherapeutic treatments limit its effec-
tive clinical usage. Hence, determining the safe and
effective doses of warfarin is highly critical for a specific
subset of patients.2,3
Considering the fact that genetic polymorphisms are
known to account for the interindividual variability of
humans to drugs, two important genesdVKORC1 (vitamin K
epoxide reductase complex subunit 1) and CYP2C9 (cyto-
chrome P450 family 2, subfamily C, polypeptide 9)dare
known and studied for their involvement in altered drug
metabolism and action. Warfarin’s mode of action is initi-
ated when it interacts with VKORC1 and interferes with the
vitamin K recycling in liver, thus leading to the secretion of
inactive vitamin K-dependent proteins involved in the blood
clotting mechanism.4,5 CYP2C9 is a crucial liver enzyme
known to metabolize warfarin. Hence, any change in the
gene sequence of these two genes affects the amount of
warfarin to be administered.
Previous studies have revealed the influence of CYP2C9
and VKORC1 genes on warfarin maintenance dose in
different ethnic populations.6,7,8 Furthermore, some
studies have also indicated their association with other
clinical outcomes such as time to reach a stable dose, and
events such as bleeding and retaining time within the target
therapeutic range.9,10
Several genetic variations in the VKORC1 gene are found
to influence the sensitivity of the warfarin therapy in
studies conducted worldwide.11 So far, 28 polymorphisms
have been described in this gene, but only three main
haplotypes are known to influence the whole genetic vari-
ability of VKORC1. Among them, VKORC1*2 is the most
important haplotype that accounts for the variability in
response to oral anticoagulants.12,13 Much of the variability
in warfarin therapy is attributed to the e1639G>A pro-
moter polymorphism [single nucleotide polymorphism (SNP)
in haplotype 2] of the VKORC1 gene. Similarly different
CYP2C9 variants have now been identified,14 the most
common variant, CYP2C9*1, is considered to be the wild-
type allele. The other two variantsdCYP2C9*2 and
CYP2C9*3dare known to reduce the metabolism of
warfarin, and are therefore responsible for warfarin sensi-
tivity.15,16 The functional significance of the other alleles is
yet to be fully determined.The available literature on south Indian populations
showed the variable CYP2C9*2 and *3 allelic frequency
distribution, but there are no reports on VKORC1 al-
leles.17,18 However, genotypic frequencies of VKORC1
e1639G>A, CYP2C9*2, and CYP2C9*3 have been reported in
a North Indian population.19 The United States Food and
Drug Administration (US FDA) also states that a patient’s
CYP2C9 and VKORC1 genotype information, when available,
can assist in the selection of the starting dose of warfarin.20
Therefore, it is important to screen the Indian population,
which is composed of multiethnic groups and known to
show substantial genetic variations. To our knowledge, no
reports are available on the South Indian population.
Hence, the present study was undertaken to assess the
common reported variations in VKORC1 and CYP2C9 genes
in patients undergoing warfarin therapy, because they
could be critical for dosage prediction in the clinical
setting. Additionally, an amplification refractory mutation
system (ARMS) polymerase chain reaction (PCR), a rapid
and cost-effective SNP detection method, was designed to
genotype the VKORC1 e1639G>A allele.Materials and methods
Participants
A total of 136 patients, comprising 85 males and 51 females
aged 19e87 years old, were recruited into this study from
Apollo Hospitals, Hyderabad, India. The clinical indications
for warfarin therapy were open heart surgery, DVT, rheu-
matic heart disease, and atrial fibrillation. Written
informed consent was obtained from each study participant
after a clear explanation of the study objectives and pro-
cedures involved was given. The inclusion criteria for the
case group were that each participant should be 18 years
old, and a minimum of 2 months on warfarin therapy after
the prothrombin timedinternational normalized ratio (PT-
INR) has been stabilized. The PT-INR test is used to deter-
mine the clotting tendency of blood, in the measurement of
warfarin dosage, liver damage, and vitamin K status. The
target range in the case of warfarin is usually between 2
and 3. In our study, the patients were included only after
the PT-INR was stabilized to have a better correlation of the
variable warfarin dosage in the presence of SNPs.
Patients who had cancer, renal or hepatic insufficiency,
congestive heart failure, or active alcoholism, those who
were undergoing concurrent chemotherapy, and those who
were on CYP2C9 inducer drugs were excluded from the
sampling.
Genetic variation in patients on warfarin therapy 149All patients were given dietary advice to avoid foods that
may interfere with warfarin pharmacokinetics and phar-
macodynamics, during the course of PT-INR stabilization.
Patients taking >5 mg of warfarin were categorized as
“warfarin-resistive”, whereas those taking <5 mg were
categorized as “warfarin-sensitive”.8,21,22 The control popu-
lation was selected based on the warfarin treatment with
intermediate dosage (5 mg/d) from the same patient group.
Sample collection and isolation of genomic DNA
from samples
A 1-mL blood sample from each participant was collected and
placed into potassium (K)-EDTA vacutainers. Clinical and de-
mographic details, such as age, sex, body mass index (BMI)
ratio, duration of dosage, treatment/maintenance dose of
warfarin, ethnicity, and other concomitant drugs were recor-
ded in patient case sheets. None of the patients selected for
the study were under any kind of medication that could influ-
ence/interact with warfarin dosage. The protocol of the study
was approved by the ethics committee of Apollo Hospitals,
Hyderabad as well as the ethics committee of the Department
of Genetics, Osmania University. Genomic DNA was extracted
from whole blood using the standard phenolechloroform
extraction method.23 The isolated DNA was dissolved in (Tris)-
EDTA buffer (10 mM:1 mM) and stored at80 C.
Genotyping of VKORC1 and CYP2C9 by PCR and
DNA sequencing
All patients and controls were genotyped for rs9923231,
rs9934438, rs1799853, and rs1057910 SNPs. Specific oligo-
nucleotide primers were designed using Vector NTI software






Figure 1 Map of the VKORC1 and CYP2C9 genes showing the com
P450, family 2, subfamily C, polypeptide 9; VKORC1 Z vitamin K eCYP2C9 genes for the existing mutation-prone regions (US
FDA-approved; Fig. 1) in Western populations.20 In the
VKORC1 gene, the rs9923231 SNP in the promoter region
and the rs9934438 SNP in the intron 1 region were ampli-
fied. In the CYP2C9 gene, mutant alleles 2* (rs1799853) and
3* (rs1057910) were amplified (Table 1). A standard 30-
cycle PCR program was used to amplify the four SNP
regionsd45 seconds at each of the following temperatures:
94C, 56C, and 72C.
The PCR amplicons of both VKORC1 and CYP2C9 genes
were initially purified using Nucleospin Gel and PCR cleanup
kit (Macherey-Nagel, Duren, Germany) and later subjected
to automated DNA sequencing ABI 3730 xl DNA analyzer
(Life Technologies, NY, USA). The corresponding chro-
matograms were analyzed by Chromas software (Techne-
lysium, South Brisbane, Australia), and a multiple sequence
alignment was performed using Clustal W algorithm in
Vector NTI software (Invitrogen) for screening of SNPs.
Bioinformatic analysis
An in silico analysis of a novel VKORC1 promoter mutant was
performed to predict the transcription factor (TF) binding
site. The site having a novel G insertion ate1586 positionwas
chosen along with both upstream and downstream spanning
sequencesandwasanalyzed forTFbinding site using theTESS
(Transcription Element Search System) software (University
of Pennsylvania, Philadelphia, USA) program.24
ARMS PCR assay for genotyping VKORC1
e1639G>A
The Tetra-Primer ARMS PCR method, a cost-effective and
rapid method, was developed to genotype e1639G>AExon 9 (52905-53086)
Exon 2
Exon 3
Exon 6 ( 36131-36272)
Exon 7 (45211-45398)
Exon 8 (50091-50232)
mon existing mutation prone regions. CYP2C9 Z cytochrome
poxide reductase complex subunit 1.
Table 1 List of primers designed for sequencing existing mutation prone regions in VKORC1 and CYP2C9.
Sl. no. Gene and region SNP ID Primers
1 VKORC1, promoter rs9923231 Forward 50-CAGAAGGGTAGGTGCAACAGTAAGG-30
Reverse 50-CACTGCAACTTGTTTCTCTTTCCCA-30
2 VKORC1, intron 1 rs9934438 Forward 50-AGGGGAGGATAGGGTCAGTGACATG-30
Reverse 50-TGGATTGATTGAGGATGCTGTCCTG-30
3 CYP2C9, exon 3 rs1799853 (*2) Forward 50-TACAATACAATGAAAATACATG-30
Reverse 50-CTAACAACCAGACTCATAATG-30
4 CYP2C9, exon 7 rs1057910 (*3) Forward 50-TTGGCAGAAACCGGAGCCCCTGCAT-30
Reverse 50-AATTTGGGGACTTCGAAAACATGGAGTTGC-30
CYP2C9 Z cytochrome P450, family 2, subfamily C, polypeptide 9; CYP2C9*1,*2,*3 Z different alleles of the gene; SNP Z single
nucleotide polymorphisms; VKORC1 Z vitamin K epoxide reductase complex subunit 1.
150 T. Shukla et al.promoter polymorphism in the VKORC1 gene. Primer
designing for ARMS was performed manually as described by
Ye et al.25 The primer sequences of the four primers (forward
outer and inner and reverse outer and inner) are presented in
Table 2. Each PCR reaction was carried out in a total volume
of 25 mL with 30 ng of template DNA, 10 pmol each of inner
primers, 5 pmol each of outer primers, 200 mM dNTP mix, 2
units of Taq polymerase, and appropriate concentration of
reaction buffer. The PCR program was as follows: initial
denaturation at 95C for 5minutes, 35 cycles of 30 seconds at
each of the following temperatures: 94C, 64C, and 72C,
with a final extension step at 72C for 5 minutes.Statistical analysis
Frequencies of the mutant alleles were analyzed in the study
participants along with median dosage and age. Box-plot
analysis was performed using SPSS software (SPSS Inc., Chi-
cago, IL, USA) to graphically display the dispersion and skew-
ness in the data obtained from genotyping. HardyeWeinberg
equilibrium using Chi-square test was performed by SPSS
software (SPSS Inc.) to analyze the significance of the geno-


















ARMS Z amplification refractory mutation system;
PCRZ polymerase chain reaction; VKORC1Z vitamin K epoxide
reductase complex subunit 1.p  0.05. Minor allele frequency (MAF) was also calculated
along with the mean maintenance dose in sensitive and
resistive patients with 95% confidence interval, which was
used for patient dosage correlation with the genotyping data.Results
Clinical characteristics of participants
Table 3 summarizes the dosage groups of the patients and
the primary indications for warfarin treatment showing
open heart surgery (25.73%), DVT (38.23%), rheumatic heart
disease (16.17%), and atrial fibrillation (19.85%). It also
explains the different groups of patients (sensitive and
resistive) analyzed in the study. Tables 4 and 5 summarize
the important clinical features of the sensitive and resistive
patients analyzed in the study, which include BMI, age, sex,
dosage follow-up, and time since stabilized dosage. BMI is a
measure for human body shape based on an individual’s
weight and height. A lower or higher BMI when compared to
the normal range has been reported to be responsible for
variable warfarin dosage to a small extent; therefore, we
specifically recruited individuals who were within the normalTable 3 Clinical characteristics of patients analyzed in
the study.
Dose (mg/d) 5 (1e12.5)
Age (y) 35 (19e87)
Frequency (n) of warfarin-sensitive
and warfarin-resistive patients
No. of sensitive patients 46
No. of resistive patients 22
Indications for warfarin
DVT 52 (38.23)
Open heart surgery 35 (25.73)
RHD 22 (16.17)
Atrial fibrillation 27 (19.85)
Other concomitant drugs
Digoxin, Ricobid-D, Diltiazem/Enalapril, Encort, Telmisartan
Data are presented as n (%) or median (range).
DVT Z deep vein thrombosis; RHD Z rheumatic heart disease.













1 WAR002 35/M 27.1 DVT 2 2
2 WAR007 34/M 24.0 Open heart surgery 6 4
3 WAR008 28/M 25.6 DVT 5 3
4 WAR014 30/M 22.5 Atrial fibrillation 10 1.5
5 WAR015 22/M 25.7 Open heart surgery 8 2
6 WAR016 35/M 23.8 DVT 4 2
7 WAR018 39/F 27.8 DVT 8 4
8 WAR020 50/F 20.9 DVT 5 2.5
9 WAR022 35/F 27.8 Open heart surgery 9 2.5
10 WAR025 28/M 18.7 Atrial fibrillation 12 4
11 WAR028 22/M 27.1 DVT 6 3.5
12 WAR034 24/F 22.6 DVT 4 3.5
13 WAR038 60/F 27.4 Open heart surgery 7 2.5
14 WAR040 57/M 21.8 Atrial fibrillation 8 2.5
15 WAR042 60/F 24.6 DVT 10 4
16 WAR045 24/M 19.5 DVT 2 3
17 WAR050 61/M 23.6 DVT 7 4
18 WAR052 35/M 27.1 Atrial fibrillation 10 2
19 WAR057 34/M 24.0 Open heart surgery 10 4
20 WAR058 28/M 19.6 DVT 6 4
21 WAR064 30/M 22.5 DVT 7 1.5
22 WAR065 22/M 25.7 Atrial fibrillation 10 2
23 WAR066 35/M 23.8 DVT 7 2
24 WAR068 39/F 25.8 Open heart surgery 12 4
25 WAR070 50/F 20.9 Open heart surgery 12 2.5
26 WAR072 35/F 25.8 Atrial fibrillation 9 2.5
27 WAR075 28/M 26.7 Open heart surgery 8 4
28 WAR078 22/M 27.1 DVT 2 2.5
29 WAR084 24/F 22.6 Atrial fibrillation 10 3.5
30 WAR088 60/F 27.4 DVT 12 2.5
31 WAR090 67/M 21.8 DVT 9 2.5
32 WAR092 60/F 24.6 DVT 12 4
33 WAR095 24/M 19.5 Atrial fibrillation 8 3
34 WAR100 61/M 23.6 DVT 8 4
35 WAR102 35/M 27.1 Open heart surgery 16 2
36 WAR107 34/M 24.0 DVT 8 2
37 WAR108 28/M 18.6 DVT 7 4
38 WAR114 30/M 22.5 Atrial fibrillation 12 1.5
39 WAR115 22/M 18.7 DVT 8 2
40 WAR116 35/M 23.8 Atrial fibrillation 14 2
41 WAR118 39/F 25.8 DVT 16 4
42 WAR120 50/F 20.9 Open heart surgery 9 2.5
43 WAR122 35/F 23.8 DVT 14 2.5
44 WAR125 28/M 18.7 DVT 9 4
45 WAR128 22/M 27.1 Open heart surgery 7 2.5
46 WAR134 24/F 22.6 DVT 8 4
BMIZ body mass index; DVTZ deep vein thrombosis; FZ female; MZmale; PT-INRZ prothrombin timedinternational normalized ratio.
Genetic variation in patients on warfarin therapy 151BMI range to avoid discrepant results. Mean agewas similar for
both sexes. The other concomitant drugs administered to the
patients, such as Digoxin, Ricobid-D, Enalapril, Encort, and
Telmisartan, do not have anymajor interaction withwarfarin.
These drugs, when coadministered along with warfarin, have
not been reported for any dosage variation.Distribution of VKORC1 and CYP2C9 genotypes
The four specific regions in the two genes (either VKORC1 or
CYP2C9) were successfully amplified using PCR (Fig. 2). The
DNA sequences of PCR amplicons were analyzed by Clustal
Table 5 Clinical features of warfarin-resistive patients analyzed in the study.








1 WAR003 25/F 27.6 DVT 6 12
2 WAR013 19/M 19.2 DVT 2 6
3 WAR023 24/M 18.9 Open heart surgery 12 6
4 WAR033 32/M 26.7 Open heart surgery 10 6
5 WAR035 30/F 27.1 DVT 6 6
6 WAR039 29/F 19.6 Atrial fibrillation 16 7.5
7 WAR044 36/M 24.1 Open heart surgery 3 7
8 WAR049 23/F 24.8 DVT 3 6
9 WAR053 25/F 25.3 DVT 2 11
10 WAR063 19/M 17.2 DVT 6 6
11 WAR073 24/M 17.9 DVT 5 6
12 WAR081 50/F 26.1 DVT 8 6
13 WAR083 32/M 26.7 Open heart surgery 12 6
14 WAR085 30/F 27.1 RHD 16 6
15 WAR089 29/F 19.6 DVT 6 7.5
16 WAR094 36/M 27.3 DVT 5 6
17 WAR099 23/F 24.8 Open heart surgery 8 6
18 WAR103 25/F 25.1 DVT 12 12
19 WAR113 19/M 17.2 DVT 6 6
20 WAR123 24/M 15.9 Atrial fibrillation 12 6
21 WAR133 42/M 26.7 RHD 18 6
22 WAR135 30/F 27.1 Open heart surgery 9 6
BMI Z body mass index; DVT Z deep vein thrombosis; F Z female; M Z male; PT-INR Z prothrombin timedinternational normalized
ratio; RHD Z rheumatic heart disease.
152 T. Shukla et al.W algorithm to identify the genotype of individuals. Table 6
shows the frequency of genotype distributions for VKORC1
e1639G>A (rs9923231), VKORC1 1173C>T (rs9934438),
CYP2C9*2 6313 C>T (rs1799853), and CYP2C9*3 45324 A>C
(rs1057910) polymorphisms and novel G insertion at e1586
position in the VKORC1 promoter region.
The frequencies of homozygotes for the *2 and *3 CYP2C9
variants were low as expected (2.20% and 0.735%, respec-
tively),whereas those for homozygotesofVKORC1e1639G>AFigure 2 (A) VKORC1 gene regions rs9923231 and rs9934438 ampli
CYP2C9 gene regions rs1799853 and rs1057910 amplified at 610 bp (
ladder (G Biosciences, USA). CYP2C9 Z cytochrome P450, family 2andVKORC1 1173C>Twere 7.3% and 1.47%, respectively. The
frequencies of the two heterozygous genotypes CYP2C9*1/*2
and CYP2C9*1/*3 were 3.67% and 2.20%, respectively,
whereas compound heterozygotes of CYP2C9*2/*3 amounted
to 5.87%. VKORC1e1639G>A heterozygotes comprised 8.8%,
whereas VKORC1 1173C>T heterozygotes accounted for 2.2%
of the total patient samples analyzed. None of the patient
samples had more than one SNP out of the four SNPS
mentioned above.fied at 560 bp (lane 1) and 570 bp (lane 3), respectively, and (B)
lane 2) and 600 bp (lane 3), respectively, along with 100 bp DNA
, subfamily C, polypeptide 9.
Table 6 Allele frequencies, minor allele frequency, mean dosage, and two-tailed p value of SNPs observed in warfarin-
















1 VKORC1 22 e 2.18 (1.99e2.36) 11.7 0.0014
1639G>A
2 VKORC1 5 e 3.8 (3.73e3.86) 2.57 0.0001
1173C>T
3 CYP2C9*2 8 e 2.87 (2.78e2.95) 4.04 0.0001
4 CYP2C9*3 4 e 3.75 (3.67e3.82) 1.837 0.0001
5 VKORC1
3725 G “INS”
e 4 9.37 (9.00e9.73) 2.94 0.0001
CI Z confidence interval; CYP2C9 Z cytochrome P450, family 2, subfamily C, polypeptide 9; CYP2C9*1,*2,*3Z different alleles of the
gene; VKORC1 Z vitamin K epoxide reductase complex subunit 1.
a Two-tailed Chi-square test.
Genetic variation in patients on warfarin therapy 153Correlation of gene polymorphism data with
warfarin dosage
Of the 136 individuals genotyped, 46 were warfarin-
sensitive and 39 were polymorphic to existing mutant al-
leles (SNPs in either VKORC1 or CYP2C9 gene, as listed in
Table 6), which accounts for 84.78% of warfarin-sensitive
patients with mutant alleles.
One novel mutation was observed in four patients in the
VKORC1 gene with an insertion of G at e1586 position in the
promoter region of the VKORC1 gene (Fig. 3). Interestingly,
e1586 G insertion has co-occurred with e1639G>A muta-
tion in all these patients.
As described previously, VKORC1 e1639G>A poly-
morphism is related to warfarin sensitivity, but in our study,
all the patients (having the novel G insertion and
e1639G>A mutation in VKORC1 promoter) were on a higher
dosage of warfarin, when compared to the intermediate
dose. The promoter sequence having the novel mutation
was submitted to Genbank (NCBI) with accession number
JQ363929.1. The four sequences in which the novel inser-
tion was present were submitted as a population set to
NCBI; accession number, PopSet: 392259206.
In silico predictive analysis
TESS analysis showed that the addition of an extra G in the
VKORC1 promoter sequence increases the probability of a
putative TF binding site being created at the mutated po-
sition. The increased probability for a TF binding site could
be the reason for the higher transcriptional activity of the
VKORC1 gene in patients having mutations (Ins-G e1586).
ARMS analysis
The Tetra primer ARMS method was successfully tested for
the genotyping of the VKORC1 e1639G>A promoter poly-
morphism. Samples with wild-type allele and mutant al-
leles, both homozygous and heterozygous as confirmed by
automated DNA sequencing results, were subjected toARMS PCR. Gene sequencing results were successfully
correlated with the results of ARMS PCR (Fig. 4). The sizes
of amplified DNA fragments on agarose gel were 260 bp,
180 bp, and 130 bp (Fig. 4). The 260-bp band is amplified by
outer primers and would be present in both wild-type and
mutant samples. The 180-bp band is for the G allele and
would be present along with the 260-bp band in wild-type
samples. The 130-bp band is for the A allele and would be
present along with the 260-bp band in the case of mutant
homozygous and along with both 260 bp and 180 bp in the
case of mutant heterozygous.
Statistical analysis
Box-plot analysis results are displayed in Fig. 5. The boxes
indicate the median and interquartile ranges. The hori-
zontal lines at the ends of boxes indicate the minimum and
maximum values. Of the five mutant alleles analyzed,
VKORC1 e1639G>A was seen to influence the lowest dosage
regime in the sensitive group, followed by the CYP2C9*2
allele, whereas the other two alleles (VKORC1 1173C>T and
CYP2C9*3) had a moderate effect on dosage. VKORC1
e1586G insertion also had a significant effect in the in-
crease of dosage in the patient samples where it was
observed. HardyeWeinberg equilibrium was tested by using
the two-tailed Chi-square test, with 1 degree of freedom
(Table 6), to analyze the significance of the mutant alleles
in dosage administration as obtained by genotyping. The
frequency of the alleles (observed and expected) was found
to be statistically significant with lower p values, as
expected.
Discussion
The present genotyping study was carried out in 136 patient
samples from South India for VKORC1 and CYP2C9 gene
polymorphisms. All blood samples were collected from
patients who visited Apollo Hospitals in Hyderabad. This
study investigated the frequency of VKORC1 and CYP2C9
gene polymorphisms and their relation to warfarin dose in
Figure 3 DNA sequencing chromatogram showing (A) the insertion of G at 3725 position (e1586 G Ins with respect to the start
codon) in the VKORC1 gene promoter region, and (B) the wild-type gene promoter without any insertion. G Z guanidine;
VKORC1 Z vitamin K epoxide reductase complex subunit 1.
154 T. Shukla et al.patients with DVT, open heart surgery, atrial fibrillation,
and rheumatic heart disease.
Earlier studies have classified various ethnic populations on
the basis of warfarin dosage regime into lower (3 mg/d), in-
termediate (5 mg/d), and higher dose (6.5 mg/d) groups.8Figure 4 VKORC1 e1639G>AdARMS analysis results; ampli-
fied fragments in patient sample with wild-type allele GG (lane
1), mutant heterozygous GA (lane 2), and mutant homozygous
AA (lane 3). ARMSZ amplification refractory mutation system;
VKORC1 Z vitamin K epoxide reductase complex subunit 1.The allele frequencies for VKORC1 e1639G>A, CYP2C9*2,
andCYP2C9*3 and their correlationwith clinical data observed
in the present study were in agreement with those observed in
other population groups worldwide. A study conducted on a
North Indian population reported allele frequencies for
VKORC1 e1639 A, CYP2C9*2, and CYP2C9*3 to be 14.22%,
4.90%,and3.92%, respectively,26whereas inour studyonSouth
Indian patients, the genotype frequencies recorded were
slightly higher, that is, 16.2%, 5.89%, and 2.95%, respectively.
In our study population, we found out that approxi-
mately 58% of the variance in warfarin dose in sensitive
patients was explained by the VKORC1 genotypes alone,
whereas approximately 26% of the variance in sensitiveFigure 5 Box-plot analysis. Boxes indicate the median and
interquartile ranges.Horizontal lines at theends of boxes indicate
theminimum andmaximum valuesdbox-plot of different mutant
alleles of VKORC1 and CYP2C9 plotted against warfarin dosage
(mg/d). CYP2C9 Z cytochrome P450, family 2, subfamily C,
polypeptide 9; VKORC1Z vitamin K epoxide reductase complex
subunit 1.

















1 WAR044 36/M 24.15 Open heart
surgery
3 7 Digoxin, Ricobid-D
2 WAR053 25/F 25.32 DVT 2 11 Diltiazem/Enalapril
3 WAR089 29/F 19.66 DVT 6 7.5 Digoxin, Encort
4 WAR103 25/F 25.12 DVT 12 12 Diltiazem/Enalapril
BMI Z body mass index; DVT Z deep vein thrombosis; F Z female; M Z male; PT-INR Z prothrombin timedinternational normalized
ratio; VKORC1 Z vitamin K epoxide reductase complex subunit 1.
Genetic variation in patients on warfarin therapy 155patients was explained by CYP2C9 genotypes. The VKORC1
genotypes appeared to be the most important genetic
factor determining the variability in warfarin dose in Indian
patients as its effect was approximately two times that of
the CYP2C9 genotype. Therefore, we designed an ARMS PCR
assay for genotyping of VKORC1 e1639G>A SNP, because
this mutation alone explains (in most cases) the variance of
dosage in sensitive patients.
Data available from scanty reports in Indian populations
describes the observed mutations with low dosage regime
in warfarin-treated patients, but we also found out that in
the presence of novel mutation (insertion of G), along with
VKORC1 promoter e1639G>A mutation, the dosage amount
significantly increases. VKORC1 e1639G>A promoter mu-
tation correlated with low dosage regime in most of the
patients as explained by the US FDA guidelines, except for
four patients, who were on a higher dosage of warfarin in
spite of the presence of a predominant VKORC1 e1639G>A
promoter mutation. The clinical features of the four pa-
tients are shown in Table 7. None of them were on warfarin
dosage inducer medications or diet. Sequence analysis of
the promoter region of the VKORC1 gene showed the
presence of a novel mutation (insertion of G at e1586 po-
sition) in all four patients. Patients carrying both VKORC1
promoter mutations were on a higher maintenance dose,
which is not observed among patients carrying the VKORC1
e1639G>A genotype alone. This was an important finding,
and therefore genetic analysis should be done on a larger
number of patients to establish the role of G insertion in
warfarin dosage maintenance. This may help to improve
the accuracy of warfarin sensitivity tests when both pro-
moter mutations are considered for genotyping.
We also hypothesize that the level of VKORC1 protein
expression is upregulated by the VKORC1 e1586 G insertion
in the promoter region, which in turn accounts for the
higher dosage requirements in patients. We predict that
this mutation creates a possible binding site for regulatory
proteins (enhancers), thereby leading to a higher dosage
regime. Further functional studies for this mutation should
help in the validation of its role as an enhancer and its
inclusion as a genotyping marker in warfarin sensitivity
tests.
In conclusion, the present study clearly demonstrates that
genotyping of patients for VKORC1 and CYP2C9 genes would
help in proper dosage prediction for stabilizing INR, and
probably provides a strong argument for the routine adoption
of pharmacogenomic testing in our population group.It is known that SNPs play a major role in the variability
of warfarin dosage worldwide, and different algorithms are
in place for predicting the therapeutic dosage of warfarin
at the clinical level. These algorithms take into account the
genetic and nongenetic factors for dosage prediction and
are accepted by clinicians.
Therefore, in India, where multiethnic groups coexist
and where very few studies have been conducted on
warfarin genetics, the genotyping results could be applied
to clinical warfarin therapy if large-scale studies are con-
ducted on Indian populations. As we have also found a novel
mutation in the VKORC1 gene that leads to warfarin re-
sistivity even in the presence of e1639G>A mutation
(known for warfarin sensitivity), screening a large number
of Indian patients is necessary to avoid discrepant results
and for the implementation of these tests at the clinical
level.
To our knowledge, this is the first report on the insertion
of G in the promoter region of VKORC1 at e1586 position.
This might have an influence on warfarin resistance, indi-
cating that it may play a significant role in the treatment
regime as a diagnostic marker.Acknowledgments
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